<DOC>
	<DOCNO>NCT01286974</DOCNO>
	<brief_summary>A pharmacokinetic study access body absorbs remove linifanib male patient advance solid tumor .</brief_summary>
	<brief_title>A Pharmacokinetic Study Access How Body Absorbs Removes Linifanib Male Patients With Advanced Solid Tumors .</brief_title>
	<detailed_description>This study design assess mass balance [ 14C ] linifanib metabolic profile linifanib 4 subject advance solid tumor follow single oral dose . Subjects may continue linifanib completion metabolism study . The result study determine exposure major metabolite excretion pathway ( ) parent drug metabolite linifanib human .</detailed_description>
	<criteria>Inclusion Criteria Subject must &gt; /= 18 year age . Subject must histologically cytologically confirm nonhematologic malignancy . Eastern cooperative Oncology Group ( ECOG ) Performance Score 0 2 . Subject must adequate bone marrow , renal hepatic function . Subject must Partial Thromboplastin Time ( PTT ) &lt; /= 1.5 x Upper Limit Normal ( ULN ) International Normalized Ratio ( INR ) &lt; /= 1.5 . Subject must capable understand comply parameter outline protocol able sign inform consent . Exclusion Criteria Subject receive previous administration radiolabeled research substance within 12 month prior Study Day 1 exposure significant radiation ( e.g. , barium meal , etc . ) within past 3 month within period define 5 halflives , whichever short , prior Study Day 1 . Subject receive anticancer therapy include investigational agent , cytotoxic chemotherapy , radiation , hormonal biologic therapy within 21 day within period define 5 halflives , whichever short , prior Study Day 1 . Subject currently use know inhibitor ( e.g. , ketoconazole ) inducer ( e.g. , rifampin ) cytochrome P450 3A ( CYP3A ) within 1 month prior Study Day 1 . Subject recover less equal grade 1 clinically significant adverse effects/toxicities previous therapy . Subject undergone major surgery within 21 day Study Day 1 . The subject brain meningeal metastasis . The subject nonsmall cell lung cancer ( NSCLC ) predominant squamous cell histology . Subject receive therapeutic anticoagulation therapy . Subject history of/or currently exhibit clinically significant event bleed ( e.g. , hemoptysis ) . Subject proteinuria Common Terminology Criteria ( CTC ) Grade &gt; 2 baseline . Subject currently exhibit symptomatic persistent , uncontrolled hypertension . Subject history myocardial infarction within 6 month . Subject know autoimmune disease renal involvement . Subject receive combination antiretroviral therapy human immunodeficiency virus ( HIV ) . Clinically significant uncontrolled conditions/medical symptom . Subject document left ventricular ( LV ) ejection fraction &lt; 50 % . Subject previously receive linifanib .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>